Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916873 | 0.85 | MGLL (0.45) | P2RX7MGLLMAPTHDAC6MET | |
| SCHEMBL21423631 | 0.83 | P2RX7 (0.56) | P2RX7MGLLGSK3BDYRK1AMAPT | |
| SCHEMBL12208887 | 0.79 | P2RX7 (0.53) | P2RX7GSK3BDYRK1AMAPTHDAC6 | |
| SCHEMBL25976627 | 0.79 | P2RX7 (0.53) | P2RX7GSK3BDYRK1AHDAC6 | |
| SCHEMBL16219065 | 0.78 | MGLL (0.48) | P2RX7MGLLHDAC6MET | |
| SCHEMBL5787821 | 0.78 | P2RX7 (0.45) | P2RX7MGLLGSK3BDYRK1AHDAC6 | |
| SCHEMBL16219018 | 0.74 | DPP4 (0.49) | MGLLMET | |
| SCHEMBL16219046 | 0.74 | SCD (0.46) | P2RX7MGLLGSK3BDYRK1AMET | |
| SCHEMBL12284031 | 0.73 | P2RX7 (0.54) | P2RX7GSK3BDYRK1AHDAC6CNR1 | |
| SCHEMBL23011668 | 0.73 | MGLL (0.42) | P2RX7MGLLHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | P2RX7 523/4885MGLL 758/4885GSK3B 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.